RSV Vaccine
Introducing ABRYSVO™: The RSV Vaccine for Adults 60 and Older
At NIMVAX, we’re committed to offering a comprehensive suite of vaccinations designed to protect public health. We’re proud to introduce ABRYSVO™, a specialized RSV vaccine for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in people 60 years and older.
Understanding RSV and Its Risks
Respiratory syncytial virus, commonly known as RSV, is a highly contagious virus that can lead to severe respiratory disease. Although the symptoms may resemble a common cold, RSV can be particularly dangerous for adults 60 and older. Those with underlying conditions like COPD, asthma, and heart disease are at even higher risk for severe complications.
How RSV is Transmitted
RSV spreads easily through respiratory droplets when an infected person coughs or sneezes. It can also live on surfaces, making it essential to maintain good hygiene practices. The high contagion factor of RSV warrants serious preventative measures, particularly for vulnerable populations.
Why ABRYSVO™ is the Right Choice
ABRYSVO™ is designed to work with your immune system to create antibodies against RSV. In a clinical trial involving over 34,000 adults aged 60 and older, ABRYSVO™ was proven effective in helping to protect against severe RSV cases. This RSV vaccine is the ideal addition to your preventative healthcare plan.
What to Expect: Possible Side Effects
Like all vaccines, ABRYSVO™ has been rigorously tested for safety and efficacy. The most common side effects include fatigue, headache, pain at the injection site, and muscle pain. These symptoms are generally mild and a sign that your body is building immunity.
Don’t leave your health to chance.
If you’re 60 years old or older, getting the ABRYSVO™ RSV vaccine could be a vital step in protecting yourself from severe respiratory disease. Schedule your appointment today at NIMVAX and be a part of our mission — “Promoting healthier communities one vaccination at a time.”
